Legal Matters (Tables)

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Schedule of Loss Contingencies by Contingency

Post-Grant Proceedings Before USPTO

Company Patent(s)	Challenger(s)	Type of Challenge	Date of Challenge	Latest Events/Current Status
U.S. Patent Nos. 10,406,226 (the "'226 Patent") and 10,464,992 (the "'992 Patent")	Anonymous parties	Ex parte reexamination	February 11, 2020	On September 11, 2023, the USPTO dismissed the '226 Patent reexamination proceedings following the Company’s filing of a Notice of Disclaimer, disclaiming all claims of the '226 Patent. On September 8, 2023, the '992 Patent reexamination proceedings were stayed by the USPTO pending resolution of the inter partes review ("IPR") of the '992 Patent initiated by Celltrion, Inc., as discussed further below.
U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent")	Mylan Pharmaceuticals Inc., Apotex Inc., and Celltrion, Inc.	IPR petitions seeking declarations of invalidity	May 5, 2021	On November 9, 2022, the USPTO issued final written decisions finding that the claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of the USPTO written decisions concerning the '338 and '069 Patents with the Federal Circuit.
U.S. Patent Nos. 10,130,681 (the "'681 Patent"), 10,888,601 (the "'601 Patent"), and 10,857,205 (the "'205 Patent")	Mylan	IPR petitions seeking declarations of invalidity	July 1, 2022 ('681 Patent and '601 Patent) October 28, 2022 ('205 Patent)	IPR proceedings concerning the '681 Patent and the '601 Patent instituted on January 11, 2023; oral hearing held on October 25, 2023. On March 1, 2023, the USPTO denied institution of Mylan's IPR petition against the '205 Patent following the Company's filing of a Notice of Disclaimer with the USPTO, disclaiming all claims of the '205 Patent.
'681 Patent and '601 Patent	Samsung Bioepis Co., Ltd.	IPR petitions seeking declarations of invalidity	January 6, 2023 ('681 Patent) March 26, 2023 ('601 Patent)	On July 19, 2023 and October 20, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent, respectively.
U.S. Patent No. 11,253,572 (the "'572 Patent")	Apotex	IPR petitions seeking declaration of invalidity	September 9, 2022	On March 10, 2023, the USPTO declined to institute an IPR proceeding.
	Samsung Bioepis Co., Ltd.	IPR petition seeking declaration of invalidity	April 27, 2023	Decision whether to institute pending.
'992 Patent and '226 Patent	Celltrion	IPR petitions seeking declarations of invalidity	January 17, 2023 ('992 Patent) February 28, 2023 ('226 Patent)	On July 20, 2023, the USPTO instituted an IPR proceeding concerning the '992 Patent. On September 1, 2023, the USPTO denied institution of Celltrion's IPR petition against the '226 Patent following the Company’s filing of a Notice of Disclaimer with the USPTO, disclaiming all claims of the '226 Patent.

Post-Grant Proceedings

Authority/Court	Company Patent(s)	Challenger(s)	Type of Challenge	Date of Challenge	Latest Events/Current Status
EPO	European Patent No. 2,944,306 (the "'306 Patent")	Anonymous parties	Opposition proceedings	October 26 and October 27, 2021	Oral hearing to be scheduled.
EPO	European Patent No. 3,716,992 (the "EP '992 Patent")	Amgen and three anonymous parties	Opposition proceedings	May 5-10, 2023	Oral hearing to be scheduled.
German Federal Patent Court	German designation of European Patent No. 2,364,691 (the "'691 Patent")	Samsung Bioepis NL B.V.	Invalidation proceedings	June 22, 2023	Oral hearing to be scheduled.